The beginning of the clinical part of a new bioequivalence study
20 October 2020
CPD has received permission and is starting to conduct the clinical part of the bioequivalence study of a foreign drug used in the treatment of dementia syndrome of various origins, including Alzheimer’s disease, ischemic stroke.